This article was originally published in Start Up
PolyMedix uses a suite of proprietary, patented computational tools to create simple, easily synthesized organic small molecule compounds that mimic the activity of host defense proteins. The company's first focus is to create antibiotic candidates, and eventually, drugs for cancer and cardiovascular disease. It will seek nearer-term revenues from materials applications of its technologies.
You may also be interested in...
Designing molecules that target protein-protein interactions in transmembrane proteins, where antibodies and fragments cannot penetrate, has been difficult. Using computational methods, a group at Penn has created novel peptides that could offer a new class of reagents for studying membrane-protein folding, assembly, and signal transduction. More broadly, they could provide access to an entire new class of targets for the design of therapeutics and drug delivery systems
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.